Both in vitro and in vivo assays demonstrated that GPX1 silencing drives a mesenchymal transition phenotype and gemcitabine resistance by activating the ROS-mediated Akt/GSK3β/Snail signaling axis in pancreatic cancer cells [72]. The gene discussed is GPX1; the disease is pancreatic neoplasm.